OmniAb (OABI) Current Deferred Revenue (2021 - 2026)
OmniAb (OABI) reported Current Deferred Revenue of $2.9 million for Q1 2026, up 70.59% year-over-year from $1.7 million in Q1 2025, and down 8.26% on a QoQ basis from $3.2 million in Q4 2025.
OmniAb (OABI) has 6 years of Current Deferred Revenue data on file, last reported at $2.9 million in Q1 2026.
- Quarterly Current Deferred Revenue rose 70.59% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 70.59% YoY) and the FY2025 annual result came in at $3.2 million, up 26.44% from the prior year.
- Current Deferred Revenue declined to $2.9 million in Q1 2026 per OABI's latest filing, from $3.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $8.2 million in Q4 2022 and bottomed at $1.0 million in Q2 2025.
- The 5-year median for Current Deferred Revenue is $3.0 million (2024), against an average of $4.3 million.
- The widest annual swing landed in 2025, when Current Deferred Revenue tumbled 69.26%; it then jumped 70.59% in 2026.
- Tracing OABI's Current Deferred Revenue over 5 years: stood at $8.2 million in 2022, then dropped by 16.56% to $6.8 million in 2023, then tumbled by 63.49% to $2.5 million in 2024, then gained by 26.44% to $3.2 million in 2025, then dropped by 8.26% to $2.9 million in 2026.
- Per Business Quant, the three latest OABI Current Deferred Revenue figures stand at $2.9 million (Q1 2026), $3.2 million (Q4 2025), and $1.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 3.16 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 2.51 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 5.53 Mn |
| Dec 31, 2023 | 6.85 Mn |
| Sep 30, 2023 | 7.38 Mn |
| Jun 30, 2023 | 7.27 Mn |
| Mar 31, 2023 | 6.89 Mn |
| Dec 31, 2022 | 8.21 Mn |
| Dec 31, 2021 | 10.79 Mn |